Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity

Tali Gidalevitz1, Thomas Krupinski, Susana Garcia

  • 1Department of Biochemistry, Molecular Biology, and Cell Biology, Rice Institute for Biomedical Research, Northwestern University, Evanston, Illinois, United States of America.

Plos Genetics
|March 7, 2009
PubMed

Insights

Genetic background significantly influences the toxicity of mutant SOD1 in amyotrophic lateral sclerosis (ALS). Specific genetic interactions, not just protein aggregation, define disease phenotypes.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Conformational diseases, like amyotrophic lateral sclerosis (ALS), involve aggregation-prone proteins.
  • Mutations in SOD1 cause familial ALS with variable clinical presentation, suggesting genetic modifiers.
  • The precise mechanisms of SOD1 toxicity and the role of genetic background remain unclear.

Purpose of the Study:

  • To investigate the impact of genetic background on the toxicity and aggregation of mutant SOD1.
  • To establish a model system for studying genetic interactions in SOD1-related neurodegeneration.
  • To determine how genetic modifiers influence disease phenotype.

Main Methods:

  • Utilized a Caenorhabditis elegans model expressing three distinct SOD1 mutants in muscle cells.
  • Introduced temperature-sensitive mutations into the C. elegans genetic background to modulate protein stability.
  • Systematically analyzed aggregation patterns and cellular dysfunction phenotypes.

Main Results:

  • Expression of SOD1 mutants alone caused mild cellular dysfunction and heterogeneous aggregates.
  • Destabilizing mutations in the genetic background significantly enhanced SOD1 mutant toxicity.
  • Phenotype manifestation and severity depended on the specific SOD1 mutation and the genetic background modifier.

Conclusions:

  • Genetic background strongly modulates SOD1 toxicity and influences disease phenotype in ALS.
  • Disease phenotypes are shaped by genetic interactions with cellular pathways, not solely by protein misfolding and aggregation.
  • Mildly destabilizing alleles in the genetic background can reveal specific toxicities of mutant proteins.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Mutations01:39

Mutations

Overview
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...